Coronavirus Disease 2019 and Takotsubo Syndrome

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39077710

Authors

Ling Zhou

Zijun Chen

Riyue Jiang

Yimin Hu

Bin Zhu

Chun Yang

Ling Yang

Cunming Liu

Affiliations

Soon will be listed here.

Abstract

The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global public health emergency. As the number of confirmed cases increases, cardiovascular complications, such as myocardial injury and cardiac dysfunction, are evidenced. Takotsubo syndrome (TTS), which is common in the intensive care unit, is diagnosed among COVID-19 patients. There have been 68 more cases reports with over 119 patients since a COVID-19 patient with TTS was first reported on April 14, 2020. Angiotensin-converting enzyme 2 (ACE2), which is widely expressed in the lungs and heart, is the virus receptor. Nevertheless, randomized studies on COVID-19 related TTS are lacking, and the pathogenesis and pathophysiology are still unclear. Therefore, this review provides an overview of the potential pathogenesis, pathophysiology, clinical manifestations, diagnosis, and treatment strategy for TTS in the COVID-19 era based on current practices.

References

Zhang Z, Jin S, Teng X, Duan X, Chen Y, Wu Y . Hydrogen sulfide attenuates cardiac injury in takotsubo cardiomyopathy by alleviating oxidative stress. Nitric Oxide. 2017; 67:10-25. DOI: 10.1016/j.niox.2017.04.010. View

Lyon A, Bossone E, Schneider B, Sechtem U, Citro R, Underwood S . Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2015; 18(1):8-27. DOI: 10.1002/ejhf.424. View

Yoshida T, Hibino T, Kako N, Murai S, Oguri M, Kato K . A pathophysiologic study of tako-tsubo cardiomyopathy with F-18 fluorodeoxyglucose positron emission tomography. Eur Heart J. 2007; 28(21):2598-604. DOI: 10.1093/eurheartj/ehm401. View

Galiuto L, De Caterina A, Porfidia A, Paraggio L, Barchetta S, Locorotondo G . Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in Apical Ballooning or Tako-Tsubo Syndrome. Eur Heart J. 2010; 31(11):1319-27. DOI: 10.1093/eurheartj/ehq039. View

Chen W, Dilsizian V . Exploring the Pathophysiology of Takotsubo Cardiomyopathy. Curr Cardiol Rep. 2017; 19(6):53. DOI: 10.1007/s11886-017-0865-7. View

Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L . The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149(3 Pt 1):818-24. DOI: 10.1164/ajrccm.149.3.7509706. View

Kato K, Lyon A, Ghadri J, Templin C . Takotsubo syndrome: aetiology, presentation and treatment. Heart. 2017; 103(18):1461-1469. DOI: 10.1136/heartjnl-2016-309783. View

Clerkin K, Fried J, Raikhelkar J, Sayer G, Griffin J, Masoumi A . COVID-19 and Cardiovascular Disease. Circulation. 2020; 141(20):1648-1655. DOI: 10.1161/CIRCULATIONAHA.120.046941. View

Hiestand T, Hanggi J, Klein C, Topka M, Jaguszewski M, Ghadri J . Takotsubo Syndrome Associated With Structural Brain Alterations of the Limbic System. J Am Coll Cardiol. 2018; 71(7):809-811. DOI: 10.1016/j.jacc.2017.12.022. View

10.

Ciutac A, Dawson D . The role of inflammation in stress cardiomyopathy. Trends Cardiovasc Med. 2020; 31(4):225-230. DOI: 10.1016/j.tcm.2020.03.005. View

11.

Wittstein I . Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning?. Cell Mol Neurobiol. 2012; 32(5):847-57. PMC: 11498407. DOI: 10.1007/s10571-012-9804-8. View

12.

Kawano H, Ryozo Okada , Yano K . Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels. 2003; 18(1):32-9. DOI: 10.1007/s003800300005. View

13.

Mylonas K, Jenkins S, Castellan R, Ruckerl D, McGregor K, Phythian-Adams A . The adult murine heart has a sparse, phagocytically active macrophage population that expands through monocyte recruitment and adopts an 'M2' phenotype in response to Th2 immunologic challenge. Immunobiology. 2015; 220(7):924-33. PMC: 4451497. DOI: 10.1016/j.imbio.2015.01.013. View

14.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

15.

Minhas A, Hays A . Reply: Takotsubo Syndrome Associated With COVID 19: And the InterTAK Diagnosis Score?. JACC Case Rep. 2020; 2(11):1835-1836. PMC: 7413057. DOI: 10.1016/j.jaccas.2020.08.002. View

16.

Ghadri J, Wittstein I, Prasad A, Sharkey S, Dote K, Akashi Y . International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018; 39(22):2032-2046. PMC: 5991216. DOI: 10.1093/eurheartj/ehy076. View

17.

Isogai T, Matsui H, Tanaka H, Fushimi K, Yasunaga H . Early β-blocker use and in-hospital mortality in patients with Takotsubo cardiomyopathy. Heart. 2016; 102(13):1029-35. DOI: 10.1136/heartjnl-2015-308712. View

18.

Ghadri J, Wittstein I, Prasad A, Sharkey S, Dote K, Akashi Y . International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018; 39(22):2047-2062. PMC: 5991205. DOI: 10.1093/eurheartj/ehy077. View

19.

Santoro F, Ieva R, Ferraretti A, Ienco V, Carpagnano G, Lodispoto M . Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series. Cardiovasc Ther. 2013; 31(6):e133-7. DOI: 10.1111/1755-5922.12047. View

20.

Roden D, Harrington R, Poppas A, Russo A . Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation. 2020; 141(24):e906-e907. DOI: 10.1161/CIRCULATIONAHA.120.047521. View